Key Findings
The Europe non-alcoholic steatohepatitis (NASH) biomarker market is predicted to grow at a CAGR of 19.55% during the forecast period, 2021-2028. The growing awareness about NAFLD, the increasing R&D activities for developing NASH therapeutics, and the expectant launch of NASH therapeutics, are anticipated to fuel the market growth.

Market Insights
Belgium, Italy, Germany, France, the United Kingdom, Russia, Poland, and Rest of Europe, are analyzed for the Europe non-alcoholic steatohepatitis (NASH) biomarker market growth evaluation. In France, the prevalence of the alcoholic fatty liver disease is high in comparison to non-alcoholic fatty liver disease, which is attributed to the increased consumption levels of alcohol. As per the OECD data, almost 17% of the population are obese. There has been a considerable increase in the prevalence of obesity and overweight in the decade, along with surging diabetes. Moreover, France is ranked fourth with regard to clinical trials conducted for non-alcoholic fatty liver disease. Such factors are estimated to boost market growth. In Italy, the prevalence of NASH is low in comparison to other countries. However, NAFLD cases are on the rise. As per the Dionysos Study, fatty liver and elevated alanine transaminase levels were evident in 70% of the northern Italian population. According to another article, a high mortality rate due to liver diseases is expected due to the growing aging population and disability. With the increasing cases of obesity and diabetes, the cases of NASH are set to increase.

Competitive Insights
Some of the eminent companies in the market are Gilead Sciences Inc, Merck & Co, Genfit SA, Madrigal Pharmaceuticals, Novartis AG, etc.
Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments